Omeros Corporation
201 Elliott Avenue West
Seattle
Washington
98119
United States
Tel: 206.676.5000
Fax: 206.676.5005
Website: https://www.omeros.com/
Email: hr@omeros.com
About Omeros Corporation
At Omeros, we are proud of our innovative and cutting-edge science. Our world-class team has achieved scientific advances that no other group has been able to accomplish, delivering wholly new classes of therapeutics to benefit patients. We let science lead the way.
From our foundation of groundbreaking science, we continue to build and advance a deep and diverse pipeline of small-molecule and protein therapeutics. We are not interested in developing “me-too” products; instead, we are focused on tackling challenging diseases and disorders with significant unmet medical needs. The result is an exciting pipeline of first-in-class drugs with new mechanisms of action that target previously untapped receptors and enzymes.
The Omeros team is exceptionally talented, passionate, collaborative and diverse. We hire smart, creative and hard-working people who want to play a meaningful part in building a preeminent biopharmaceutical company. We come from all corners of the globe, bringing unique abilities and experiences together to provide hope to patients and their families.
437 articles with Omeros Corporation
-
Omeros Corporation Reports Third Quarter 2022 Financial Results
11/9/2022
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2022.
-
Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab
11/8/2022
Decision Denies Omeros’ Appeal Requesting Immediate Labeling Discussions.
-
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
11/4/2022
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter financial results for the period ended September 30, 2022, on Wednesday, November 9, 2022, after the market closes.
-
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
11/3/2022
Omeros Corporation announced that two presentations pertaining to Omeros’ investigational complement inhibitors will be featured at the upcoming 64th American Society of Hematology Annual Meeting, which will be held from December 10-13, 2022 in New Orleans.
-
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
10/3/2022
Omeros receives $125 million in gross proceeds in sale of a portion of projected royalties receivable on net sales of OMIDRIA.
-
In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here.
-
Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
9/15/2022
Omeros Corporation (Nasdaq: OMER) today reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC).
-
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
8/17/2022
Omeros Corporation (Nasdaq: OMER) today announced that the United States Food and Drug Administration (FDA) provided an interim response to the company’s formal dispute resolution request submitted to the Agency in June, appealing the earlier decision by the FDA review division to issue a complete response letter for the biologics license application (BLA) for narsoplimab.
-
Omeros Corporation Reports Second Quarter 2022 Financial Results
8/9/2022
Omeros Corporation (Nasdaq: OMER), today announced recent highlights and developments as well as financial results for the second quarter.
-
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
8/4/2022
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2022, on Tuesday, August 9, 2022, after the market closes.
-
FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
7/29/2022
Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
-
Omeros Announces Webcast Details for Annual Meeting of Shareholders
6/15/2022
Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually, on Friday, June 17, 2022, starting at 10:00 a.m. Pacific Time.
-
Omeros Corporation Reports First Quarter 2022 Financial Results
5/10/2022
Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2022.
-
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
5/4/2022
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2022, on Tuesday, May 10, 2022, after the market closes.
-
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
4/20/2022
Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-lethal complication of stem-cell transplantation for which there is no approved treatment.
-
Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results
3/1/2022
Omeros Corporation (Nasdaq: OMER), today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2021.
-
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
2/24/2022
Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2021, on Tuesday, March 1, 2022, after the market closes.
-
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
1/19/2022
Omeros Corporation confirmed that earlier this month the company submitted to the U.S. Food and Drug Administration its response to the Agency’s Complete Response Letter for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
-
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
12/23/2021
Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc . , an affiliate of Rayner Surgical Group Limited.
-
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
12/2/2021
Omeros Announces Agreement to Sell OMIDRIA ® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion.